The following is a summary of “Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

This page includes links to articles highlighting the top gastrointestinal cancer research published on Cancer Therapy ...

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

In this exclusive MedPage Today video, Sonja Zweegman, MD, PhD, of Amsterdam University Medical Center in the Netherlands, ...

The median progression-free survival was 6.8 months, and the median overall survival was 19.1 months. Pegylated liposomal doxorubicin (PLD) has demonstrated safety and efficacy in patients with ...

Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.

Telix Pharmaceuticals focuses on theranostic cancer treatments, combining diagnostics and targeted therapy. Find out why I'm ...

This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Cambridge: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli ...